Role of surgery for stage IIIA-N2 non-small cell lung cancer

被引:2
|
作者
Yang, Fan [1 ]
Wang, Jun [1 ]
机构
[1] Peking Univ People Hosp, Dept Thorac Surg, Beijing 100044, Peoples R China
关键词
Non-small cell lung cancer; stage IIIA-N2; surgery; CLINICAL-PRACTICE GUIDELINES; RANDOMIZED CONTROLLED-TRIAL; LONG-TERM SURVIVAL; INDUCTION CHEMOTHERAPY; SURGICAL RESECTION; NEOADJUVANT CHEMOTHERAPY; 2ND EDITION; PHASE-III; THERAPY; PNEUMONECTOMY;
D O I
10.1111/j.1759-7714.2011.00048.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Perhaps no topic other than stage IIIA-N2 non-small-cell lung cancer management is as controversial among surgeons, radiologists and medical oncologists. Much of the debate relates to the choice between surgical resection and radiation as the local controlmodality. Although limited, available evidence from randomized controlled trails raised concerns about the role of surgical resection. However, there is no perfect study, and the results should not be over-interpreted. This mini review will scrutinize these trials, focusing on the study design, results and, most importantly, limitations, and will explore the possible role of surgery for stage IIIA-N2 non-small-cell lung cancer.
引用
收藏
页码:90 / 94
页数:5
相关论文
共 50 条
  • [21] RISK OF BILOBECTOMY AFTER NEOADJUVANT CONCURRENT CHEMORADIOTHERAPY FOR STAGE IIIA-N2 NON-SMALL CELL LUNG CANCER
    Cho, Jong Ho
    Kim, Hong Kwan
    Kim, Jhingook
    Choi, Yong Soo
    Kim, Kwhanmien
    Shim, Young Mog
    Park, Keunchil
    Ahn, Yong Chan
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S878 - S878
  • [22] Induction Chemoradiotherapy (50 Gy), Followed by Resection, for Stage IIIA-N2 Non-Small Cell Lung Cancer
    Tanaka, Fumihiro
    Yokomise, Hiroyasu
    Soejima, Toshinori
    Uramoto, Hidetaka
    Yamanaka, Takeharu
    Nakagawa, Kazuhiko
    Yamamoto, Nobuyuki
    Nishimura, Yasumasa
    Niwa, Hiroshi
    Okada, Morihito
    Nakagawa, Tatsuo
    Yamashita, Motohiro
    ANNALS OF THORACIC SURGERY, 2018, 106 (04): : 1018 - 1024
  • [23] The impact of neoadjuvant immunotherapy on the clinical efficacy of stage IIIA-N2 non-small cell lung cancer patients
    Huang, Qin
    Ren, Hongbo
    Bao, Zhonghui
    Jiang, Yi
    Luo, Yan
    Yao, Lan
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2025, 146
  • [24] Adjuvant Carboplatin-based Chemotherapy in Resected Stage IIIA-N2 Non-small Cell Lung Cancer
    Ou, Wei
    Sun, Hai-bo
    Ye, Xiong
    Zhang, Bin-bin
    Yang, Hua
    Fang, Qin
    Li, Pan
    Wang, Si-yu
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (07) : 1033 - 1041
  • [25] Effects of postoperative adjuvant radiotherapy on stage IIIA-N2 non-small cell lung cancer and prognostic analysis
    Wang, Tao
    Jiang, Tao
    Han, Yong
    Zhu, Ailin
    Xin, Shaowei
    Xue, Menghua
    Xin, Xiangbing
    Lu, Qiang
    JOURNAL OF BUON, 2021, 26 (02): : 328 - 335
  • [26] PORT-First Strategy After Surgery in Patients with IIIA-N2 Non-Small Cell Lung Cancer
    Lee, Hyun Woo
    Noh, O. Kyu
    Oh, Young-Taek
    Choi, Jin-Hyuk
    Chun, Mison
    Kims, Hwanik
    Heo, Jaesung
    Ahn, Mi Sun
    Cho, Oyeon
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S574 - S574
  • [27] Chemotherapy and surgery in stage IIIa non-small cell lung cancer
    Skarin, Arthur T.
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (06) : 577 - 578
  • [28] Generalized or personalized treatment for stage IIIA-N2 non-small-cell lung cancer?
    Vansteenkiste, Johan
    Van Damme, Valerie
    Dooms, Christophe
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (10) : 1605 - 1609
  • [29] Optimal sequencing of postoperative radiotherapy and chemotherapy in IIIA-N2 non-small cell lung cancer
    Selek, Ugur
    Chang, Joe Y.
    JOURNAL OF THORACIC DISEASE, 2016, 8 (07) : 1394 - 1397
  • [30] Risk of Pneumonectomy or Bilobectomy after Neoadjuvant Concurrent Chemoradlotherapy for Stage IIIA-N2 Non-Small Cell Lung Cancer
    Cho, Jong Ho
    Choi, Yong Soo
    Shim, Young Mog
    Kim, Kwhanmien
    Kim, Jhingook
    Park, Keunchil
    Ahn, Yong Chan
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S375 - S375